RTK mutations and human syndromes: when good receptors turn bad

Abstract Mutations in receptor tyrosine kinases (RTKs) have been linked to an increasing number of inherited human disease syndromes, including dwarfism, craniosynostosis, heritable cancer susceptibility, venous malformation and Piebaldism. Both gain-of-function mutations resulting in constitutive receptor activation, and loss-of-function mutations resulting in non-functional or dominant negative receptors, have been observed. This review summarizes RTK families that are involved in inherited syndromes, describes the molecular consequences of the disease mutations, and predicts that many novel mutations remain to be identified.

[1]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[2]  N. Asai,et al.  Mechanism of ret dysfunction by Hirschsprung mutations affecting its extracellular domain. , 1996, Human molecular genetics.

[3]  D. Baltimore,et al.  Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides , 1993, Nature.

[4]  R. Adar,et al.  The Transmembrane Mutation G380R in Fibroblast Growth Factor Receptor 3 Uncouples Ligand-Mediated Receptor Activation from Down-Regulation , 2000, Molecular and Cellular Biology.

[5]  J. Heath,et al.  Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. , 1998, Human molecular genetics.

[6]  T. Gallardo,et al.  Mutations in the ligand-binding domain of the kit receptor: an uncommon site in human piebaldism. , 1996, The Journal of investigative dermatology.

[7]  E. Zackai,et al.  De novo alu-element insertions in FGFR2 identify a distinct pathological basis for Apert syndrome. , 1999, American journal of human genetics.

[8]  L. Cantley,et al.  Vascular Dysmorphogenesis Caused by an Activating Mutation in the Receptor Tyrosine Kinase TIE2 , 1996, Cell.

[9]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[10]  D. Donoghue,et al.  Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. , 1996, The EMBO journal.

[11]  Y. Yazaki,et al.  Two aberrant splicings caused by mutations in the insulin receptor gene in cultured lymphocytes from a patient with Rabson-Mendenhall's syndrome. , 1998, The Journal of clinical investigation.

[12]  Masahide Takahashi,et al.  Co‐segregation of MEN2 and Hirschsprung's disease: The same mutation of RET with both gain and loss‐of‐function? , 1999 .

[13]  Tony Pawson,et al.  Protein modules and signalling networks , 1995, Nature.

[14]  S. Hirota,et al.  Familial gastrointestinal stromal tumours with germline mutation of the KIT gene , 1998, Nature Genetics.

[15]  L. Mulligan,et al.  Mutations of the RET proto‐oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease , 1997, Human mutation.

[16]  F. Endo,et al.  Congenital insensitivity to pain with anhidrosis: novel mutations in the TRKA (NTRK1) gene encoding a high-affinity receptor for nerve growth factor. , 1999, American journal of human genetics.

[17]  K. Walsh The Protein Kinase Family , 1987 .

[18]  D. Ornitz,et al.  Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia , 1996, Nature Genetics.

[19]  D. Donoghue,et al.  Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II , 1996, Molecular and cellular biology.

[20]  M. Barbacid The Trk family of neurotrophin receptors. , 1994, Journal of neurobiology.

[21]  C. Deng,et al.  Fibroblast growth factor receptors (FGFRs) and their roles in limb development , 1999, Cell and Tissue Research.

[22]  Charis Eng,et al.  Catalytic specificity of protein-tyrosine kinases is critical for selective signalling , 1995, Nature.

[23]  T. Hunter,et al.  The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. , 1998, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[24]  M. Borrello,et al.  Loss of function effect of RET mutations causing Hirschsprung disease , 1995, Nature Genetics.

[25]  A. Munnich,et al.  Ret in human development and oncogenesis , 1997, BioEssays : news and reviews in molecular, cellular and developmental biology.

[26]  C. Birchmeier,et al.  Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. , 1998, Trends in cell biology.

[27]  P. Choyke,et al.  Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. , 1998, Cancer research.

[28]  R. Stephens,et al.  Neurotrophin signal transduction by the Trk receptor. , 1994, Journal of neurobiology.

[29]  C. Heldin,et al.  Dimerization of cell surface receptors in signal transduction , 1995, Cell.

[30]  D. Donoghue,et al.  FGFR activation in skeletal disorders: too much of a good thing. , 1997, Trends in genetics : TIG.

[31]  B. Mroczkowski,et al.  Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. , 1999, Structure.

[32]  C. Marshall,et al.  Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors , 1999, Oncogene.

[33]  G. Yancopoulos,et al.  Dominant mutations in ROR2, encoding an orphan receptor tyrosine kinase, cause brachydactyly type B , 2000, Nature Genetics.

[34]  S. Hubbard,et al.  Crystal structure of the tyrosine kinase domain of the human insulin receptor , 1994, Nature.

[35]  J. Burn,et al.  Novel mutations and deletions of the KIT (steel factor receptor) gene in human piebaldism. , 1995, American journal of human genetics.

[36]  R. Ferrell,et al.  Hereditary lymphedema: evidence for linkage and genetic heterogeneity. , 1998, Human molecular genetics.

[37]  S. Shoelson,et al.  Structure of the IRS-1 PTB Domain Bound to the Juxtamembrane Region of the Insulin Receptor , 1996, Cell.

[38]  C. R. Kahn,et al.  Genetics of non-insulin-dependent (type-II) diabetes mellitus. , 1996, Annual review of medicine.

[39]  J. Kuriyan,et al.  Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: Crystal structures of the complexed and peptide-free forms , 1993, Cell.

[40]  D. Donoghue,et al.  A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. , 1999, American journal of human genetics.

[41]  R. Spritz,et al.  Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism. , 1992, American journal of human genetics.

[42]  W. Fantl,et al.  Signalling by receptor tyrosine kinases. , 1993, Annual review of biochemistry.

[43]  J. Bautista,et al.  Congenital insensitivity to pain with anhidrosis , 1980, Muscle & nerve.

[44]  H. Tonoki,et al.  Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis , 1996, Nature Genetics.

[45]  A. Bridges,et al.  A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. , 1994, Science.

[46]  Vittorio,et al.  Molecular heterogeneity of RET loss of function in Hirschsprung's disease. , 1996, The EMBO journal.

[47]  Thomas N. Sato,et al.  Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.

[48]  D. Chopin,et al.  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[49]  D. Johnson,et al.  Structural and functional diversity in the FGF receptor multigene family. , 1993, Advances in cancer research.

[50]  Cori Bargmann,et al.  Oncogenic activation of the neu‐encoded receptor protein by point mutation and deletion. , 1988, The EMBO journal.

[51]  D. Baltimore,et al.  Modular binding domains in signal transduction proteins , 1995, Cell.

[52]  S. Hubbard Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog , 1997, The EMBO journal.

[53]  D. Sanders,et al.  Human piebaldism: relationship between phenotype and site of kit gene mutation , 1995, The British journal of dermatology.

[54]  A. Bardelli,et al.  Novel mutation in the ATP‐binding site of the MET oncogene tyrosine kinase in a HPRCC family , 1999, International journal of cancer.

[55]  Joseph Schlessinger,et al.  Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism , 1996, Cell.

[56]  T. Hunter,et al.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. , 1988, Science.

[57]  T. Hunter,et al.  Receptor protein-tyrosine kinases and their signal transduction pathways. , 1994, Annual review of cell biology.

[58]  W. Marston Linehan,et al.  Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas , 1998, Nature Genetics.

[59]  G. D. Vita,et al.  Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines , 1998, Oncogene.

[60]  D. Heitjan,et al.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Marius Sudol,et al.  From Src Homology domains to other signaling modules: proposal of the `protein recognition code' , 1998, Oncogene.

[62]  C. Eng RET proto-oncogene in the development of human cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  M. Quon,et al.  Insulin signalling: metabolic pathways and mechanisms for specificity. , 1999, Cellular signalling.

[64]  C. Eng Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. , 1996, New England Journal of Medicine.

[65]  A. N. Meyer,et al.  Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[66]  E. Schröck,et al.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.

[67]  M. Saarma,et al.  GDNF Family Neurotrophic Factor Signaling: Four Masters, One Servant? , 1999, Molecular and Cellular Neuroscience.

[68]  W. Gullick,et al.  Neu receptor dimerization , 1989, Nature.

[69]  A. Kazlauskas,et al.  Phospholipase C-γ1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal , 1993, Cell.

[70]  G. Kosztolányi Leprechaunism / Donohue syndrome / insulin receptor gene mutations: a syndrome delineation story from clinicopathological description to molecular understanding , 1997, European Journal of Pediatrics.